Spero Therapeutics (SPRO) Reports Complete Patient Enrollment in Pivotal Phase 3 Clinical Trial (ADAPT-PO) of Oral Tebipenem HBr versus Intravenous Ertapenem - StreetInsider.com

Spero Therapeutics (SPRO) Reports Complete Patient Enrollment in Pivotal Phase 3 Clinical Trial (ADAPT-PO) of Oral Tebipenem HBr versus Intravenous Ertapenem  StreetInsider.com

Comments

Popular posts from this blog

(2019-2028) Global Otitis Media Market Insights, Epidemiology - TOP Tribune